k Erectile dysfunction drug and target Phosphodiesterase enzymes PDE catalyze the degradation of cGMP, a molecular regulator of ion channels, cellular apoptosis programmed cell death and smooth muscle tissue. In particular, drugs that inhibit PDE5 have been successful in the treatment of erectile dysfunction. This figure shows a model vardenafil Levitra bonded to the active site of PDE5, which includes a magnesium2 ion pink and a zinc2 ion grey. For vardenafil the atoms are represented as spheres and are colourcoded carbon black, hydrogen white, nitrogen blue, oxygen red and sulphur yellow. Stock Photo - Afloimages
Sign up
Login
All images
Erectile dysfunction drug and target Phosphodiesterase enzymes  PDE  catalyze the degradation of cGMP, a molecular regulator of ion channels, cellular apoptosis  programmed cell death  and smooth muscle tissue. In particular, drugs that inhibit PDE 5 have been successful in the treatment of erectile dysfunction. This figure shows a model vardenafil  Levitra  bonded to the active site of PDE 5, which includes a magnesium 2   ion  pink  and a zinc 2   ion  grey . For vardenafil the atoms are represented as spheres and are colour coded: carbon  black , hydrogen  white , nitrogen  blue , oxygen  red  and sulphur  yellow .
RM

Erectile dysfunction drug and target

Phosphodiesterase enzymes (PDE) catalyze the degradation of cGMP, a molecular regulator of ion channels, cellular apoptosis (programmed cell death) and smooth muscle tissue. In particular, drugs that inhibit PDE-5 have been successful in the treatment of erectile dysfunction. This figure shows a model vardenafil (Levitra) bonded to the active site of PDE-5, which includes a magnesium(2+) ion (pink) and a zinc(2+) ion (grey). For vardenafil the atoms are represented as spheres and are colour-coded: carbon (black), hydrogen (white), nitrogen (blue), oxygen (red) and sulphur (yellow).

Details

ID
170066921

Collection

License type
Rights Managed

Photographer



Sign in
Member access
Login not found.